STOCK TITAN

Biotricity Inc - BTCY STOCK NEWS

Welcome to our dedicated news page for Biotricity (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biotricity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biotricity's position in the market.

Rhea-AI Summary
Biotricity Inc. (NASDAQ:BTCY) to host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21, 2024. CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou to provide insights. Investors can access the webcast for updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Biotricity Inc. (BTCY) announces record gross margins of 73% and improved operational efficiency in its fiscal third quarter 2024 results. The company focuses on subscription-based revenue, margin improvement, and operational efficiency enhancements to achieve breakeven. Dr. Waqaas Al-Siddiq, CEO, highlights revenue growth, operational efficiency, and data utilization to drive better patient outcomes and healthcare savings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
-
Rhea-AI Summary
Biotricity Inc. (BTCY) expands its Cardiac AI Cloud platform to support predictive monitoring and earlier interventions. The company has analyzed over 360 billion heartbeats and helped diagnose over 200,000 patients, with products used in 500+ US centers. The expansion aims to enhance existing products, improve operational efficiency, and support physicians with automated analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
AI
Rhea-AI Summary
Biotricity Inc. (Nasdaq:BTCY) reports a 21.4% YOY revenue increase in Q2-FY24 to $2.9 million, with significant improvements in gross margins and a 22% reduction in SG&A. Recurring technology fees, customer device sales, continue to trend upwards, and net loss decreases by 21%. The company's CEO highlights the success of its Bioflux and Biotres products in monitoring atrial fibrillation and introduces AI-driven solutions to redefine medical diagnostics and patient care. The Q2-FY24 Financial Highlights and Operating Highlights demonstrate substantial growth and expansion in the company's services and products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
-
Rhea-AI Summary
Biotricity Inc. (Nasdaq:BTCY) announces improved margins, reduced selling expenses, and lower operating losses. The company will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14, 2023. Investors can access the webcast and a replay via the Biotricity website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.11%
Tags
conferences earnings
-
Rhea-AI Summary
Biotricity Inc. announces the expansion of its Biotres product platform with the introduction of Biotres Pro, which includes cellular backup for offline connectivity. The company has also filed a patent application for its cutting-edge 3 channel technology. With the addition of Biotres Pro, Biotricity now has the most comprehensive remote cardiac monitoring portfolio in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
none
Rhea-AI Summary
Biotricity files patent for Bioheart device, a wearable heart monitoring solution. The patent safeguards Bioheart's technology, design, and form factor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
Biotricity files patent application for Biotres device, expanding IP portfolio and increasing market barriers. CEO plans to file two additional patents within the next year. Biotres device offers continuous, real-time data on vital signs and redefines cardiac monitoring. It reduces results wait time from 2 weeks to 3 days or less.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Summary
Biotricity files patent application for Biotres device, expanding IP portfolio and increasing market barriers. CEO plans to file two additional patents within the next year. Biotres offers continuous real-time data on vital signs and redefines cardiac monitoring. Available for purchase on www.biotricity.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
Rhea-AI Summary
Biotricity launches new digital presence showcasing their healthcare technologies and solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
none
Biotricity Inc

Nasdaq:BTCY

BTCY Rankings

BTCY Stock Data

10.89M
7.88M
14.81%
3.93%
3.79%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Redwood City

About BTCY

biotricity is a medical technology company committed to improving healthcare by developing solutions that aid chronic disease prevention and management. biotricity’s premier product is bioflux, an ecg monitoring system that will be prescribed by physicians to diagnose and remotely monitor cardiac patients. biotricity is expanding medical-grade monitoring into the consumer market via its biolife solution, which empowers users to self-manage chronic conditions. biolife helps users make lifestyle changes by combining medically relevant ecg data with social media interactivity and a lifestyle log. biotricity’s r&d continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. the company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.